Skip to content

Lynx1 Capital Management LP

Follow

13F filer, CIK 1910456, DORADO, PR

Lynx1 Capital Management LP reported $646,092,908 across 31 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16. Its ten largest share positions make up 97.88% of the portfolio.

Accepted , ingested 13F-HR 0001910456-26-000007

Period
2026-09-30
Reported value
$646M
Holdings
31
Top 10 weight
97.88%
New
6
Sold out
2

Largest buys vs the previous quarter

SecurityShares changeApprox. value
DTILadded+1,807,749$11.3M
KZIAnew+225,800$2.17M
PRQRadded+1,040,680$1.73M
CCCCadded+204,224$680K
SRZNnew+20,000$644K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
AGIOreduced-2,936,331-$97.6M
STOKreduced-142,235-$3.7M
CGONexited-31,391-$2.23M
VYNEexited-1,628,700-$1.06M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001910456-26-000007, largest first. % of portfolio is the value over $646,092,908, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
GHRSGH RESEARCH PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 4,858,994 shares; 2025Q1: 6,443,940 shares; 2025Q2: 6,746,951 shares; 2025Q3: 8,601,189 shares; 2025Q4: 10,406,575 shares; 2026Q1: 10,763,288 shares; 2026Q2: 13,263,288 shares; 2026Q3: 13,263,288 shares 13,263,288$311M48.2%0Timeline
CGEMCULLINAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,257,795 shares; 2025Q1: 3,215,722 shares; 2025Q2: 4,400,842 shares; 2025Q3: 5,766,090 shares; 2025Q4: 8,963,500 shares; 2026Q1: 8,963,500 shares; 2026Q2: 8,963,500 shares; 2026Q3: 8,963,500 shares 8,963,500$138M21.3%0Timeline
STOKSTOKE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 5,187,191 shares; 2025Q1: 5,291,929 shares; 2025Q2: 5,404,674 shares; 2025Q3: 5,404,674 shares; 2025Q4: 5,404,674 shares; 2026Q1: 4,763,673 shares; 2026Q2: 4,038,404 shares; 2026Q3: 3,896,169 shares 3,896,169$101M15.68%-142,235Timeline
CCCCC4 THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 6,852,744 shares; 2025Q1: 7,098,133 shares; 2025Q2: 7,098,133 shares; 2025Q3: 7,098,133 shares; 2025Q4: 7,098,133 shares; 2026Q1: 6,998,902 shares; 2026Q2: 7,326,691 shares; 2026Q3: 7,530,915 shares 7,530,915$25.1M3.88%+204,224Timeline
DTILPRECISION BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 766,051 shares; 2025Q1: 766,051 shares; 2025Q2: 1,036,051 shares; 2025Q3: 1,042,596 shares; 2025Q4: 993,913 shares; 2026Q1: 985,113 shares; 2026Q2: 950,466 shares; 2026Q3: 2,758,215 shares 2,758,215$17.3M2.67%+1,807,749Timeline
AGIOAGIOS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 79,624 shares; 2026Q1: 2,611,568 shares; 2026Q2: 3,408,937 shares; 2026Q3: 472,606 shares 472,606$15.7M2.43%-2,936,331Timeline
KRROKORRO BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 677,915 shares; 2026Q1: 1,538,296 shares; 2026Q2: 1,538,296 shares; 2026Q3: 1,544,980 shares 1,544,980$15.3M2.37%+6,6842026-10-26, Form 4: bought 25,124 shares on 2026-10-26 Timeline
NEUPNEUPHORIA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 45,806 shares; 2025Q1: 45,806 shares; 2025Q2: 45,806 shares; 2025Q3: not reported; 2025Q4: 875,228 shares; 2026Q1: 875,328 shares; 2026Q2: 875,328 shares; 2026Q3: 875,328 shares 875,328$3.12M0.48%0Timeline
PASGPASSAGE BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 623,704 shares; 2025Q4: 623,704 shares; 2026Q1: 623,704 shares; 2026Q2: 673,759 shares; 2026Q3: 673,759 shares 673,759$3.03M0.47%0Timeline
PRQRPROQR THRAPEUTICS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 68,486 shares; 2026Q1: 68,486 shares; 2026Q2: 521,413 shares; 2026Q3: 1,562,093 shares 1,562,093$2.59M0.4%+1,040,680Timeline
TCRXTSCAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 5,357,347 shares; 2025Q1: 5,357,347 shares; 2025Q2: 7,857,347 shares; 2025Q3: 7,857,347 shares; 2025Q4: 8,019,148 shares; 2026Q1: 8,019,148 shares; 2026Q2: 8,019,148 shares; 2026Q3: 8,019,148 shares 8,019,148$2.52M0.39%0Timeline
KZIAKAZIA THERAPEUTICS LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 225,800 shares 225,800$2.17M0.34%newTimeline
PLRXPLIANT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,798,070 shares; 2026Q3: 1,798,070 shares 1,798,070$1.94M0.3%0Timeline
TRDAENTRADA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 51,689 shares; 2026Q1: 211,689 shares; 2026Q2: 178,606 shares; 2026Q3: 278,606 shares 278,606$1.77M0.27%+100,000Timeline
SRZNSURROZEN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 20,000 shares 20,000$644K0.1%newTimeline
IMTXIMMATICS N.VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 921,950 shares; 2026Q1: 216,973 shares; 2026Q2: 23,236 shares; 2026Q3: 71,263 shares 71,263$626K0.1%+48,027Timeline
HOWLWEREWOLF THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 655,926 shares; 2026Q1: 657,786 shares; 2026Q2: 657,786 shares; 2026Q3: 657,786 shares 657,786$607K0.09%0Timeline
YARWYARROW BIOSCIENCE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 22,000 shares 22,000$495K0.08%newTimeline
XNCRXENCOR INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 705,558 shares; 2026Q1: 536,398 shares; 2026Q2: 18,194 shares; 2026Q3: 18,194 shares 18,194$454K0.07%0Timeline
IMCRIMMUNOCORE HLDGS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 14,300 shares 14,300$433K0.07%newTimeline
DYNDYNE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 25,000 shares 25,000$403K0.06%newTimeline
TRAWTRAWS PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 15,078 shares; 2026Q2: 559,470 shares; 2026Q3: 559,470 shares 559,470$332K0.05%0Timeline
DNLIDENALI THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 261,687 shares; 2025Q4: 1,738,750 shares; 2026Q1: 1,880,303 shares; 2026Q2: 11,658 shares; 2026Q3: 11,658 shares 11,658$241K0.04%0Timeline
ABSIABSCI CORPORATIONQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 21,245 shares; 2026Q2: 21,245 shares; 2026Q3: 21,245 shares 21,245$229K0.04%0Timeline
FHTXFOGHORN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 61,588 shares; 2026Q3: 61,588 shares 61,588$220K0.03%0Timeline
AVTXAVALO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 10,100 shares; 2026Q3: 10,100 shares 10,100$155K0.02%0Timeline
PRMEPRIME MEDICINE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 45,000 shares 45,000$137K0.02%newTimeline
BOLTBOLT BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 30,800 shares; 2026Q2: 30,800 shares; 2026Q3: 30,800 shares 30,800$113K0.02%0Timeline
EPRXEUPRAXIA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 10,000 shares; 2026Q3: 10,000 shares 10,000$91K0.01%0Timeline
NUVBNUVATION BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 16,029 shares; 2026Q3: 16,029 shares 16,029$89.8K0.01%0Timeline
IKTINHIBIKASE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 20,000 shares; 2026Q3: 20,000 shares 20,000$1.2K<0.01%0Timeline

Sold out in Q3 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
CGONCG ONCOLOGY INC31,391$2.23Mshares
VYNEVYNE THERAPEUTICS INC1,628,700$1.06Mshares

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001910456-26-000007 base2026-11-16